3737 Market Street
About Spark Therapeutics
Spark Therapeutics is developing curative, one-time gene therapy products with the potential to transform the lives of patients and re-imagine the treatment of debilitating diseases. Spark's lead gene therapy candidate, for RPE65-related blindness, is currently in Phase 3 clinical trials with the potential to be the first approved gene therapy in the United States, and the first approved treatment to address the significant unmet needs of patients living with blindness due to inherited retinal dystrophies.
Additionally, the company has clinical and preclinical programs in other inherited retinal dystrophies and hematological disorders, and a proprietary manufacturing platform that has successfully supported human gene therapy trials across diverse therapeutic areas and routes of administration. Spark’s founding team includes scientists who led the movement to develop gene therapy as a new treatment paradigm, establishing clinical proof of concept in the eye and liver and contributing key insights to the field that have resulted in a resurgence of industry interest in gene-based medicines.
Spark is based in Philadelphia, PA and was spun out of The Children's Hospital of Philadelphia in October 2013. In May 2014, Spark announced the completion of a $72.8 million Series B financing led by Sofinnova Ventures, bringing the company's total funding raised to $82.8 million to-date. To learn more about Spark visit www.sparktx.com.
Founders: Jeffrey Marrazzo, J. Fraser Wright and Katherine High
CEO: Jeffrey Marrazzo
CTO: J. Fraser Wright
CSO (Scientific): Katherine High
Please click here for Spark Therapeutics job opportunities.
Please click here for clinical trial information.
FOLLOW SPARKS THERAPEUTICS:
Tweets by Sparks Therapeutics
166 articles with Spark Therapeutics
Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders
Spark Therapeutics and Neurochase, a company specializing in the development of scalable therapeutic strategies and enabling technology for direct delivery to the central nervous system (CNS), today announced a strategic collaboration to develop Neurochase’s proprietary delivery technology for use with selected gene therapies for rare diseases in CNS.
Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A
Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated gene therapy company today announced updated multi-year results from its Phase 1/2 clinical trial of investigational SPK-8011 for patients with hemophilia A.
Nanoscope Therapeutics will make two presentations at the 2022 ASRS meeting on their gene therapy programs to treat degenerative retinal diseases, retinitis pigmentosa and Stargardt disease.
Dark Horse Consulting Group (DHC), based in Walnut Creek, Calif., submitted proposed draft guidance to the FDA for gene therapy safety.
Drug pricing watchdog ICER issued a draft report on bluebird bio’s gene therapy betibeglogene autotemcel for beta-thalassemia. The report touted the therapy's cost-effectiveness.
Jeffrey D. Marrazzo, the co-founder of Spark Therapeutics, is stepping down as CEO of the company. The current COO, Ron Philip, will replace him.
Spark Therapeutics Announces Departure of CEO and Founder Jeff Marrazzo; COO Ron Philip Named as Successor
Spark Therapeutics, a member of the Roche Group and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced that Ron Philip, Spark’s chief operating officer, will succeed co-founder Jeffrey D. Marrazzo as chief executive officer.
Movers & Shakers, Jan. 7
1/7/2022With the turn of the calendar, biopharma and life sciences organizations have bolstered their leadership teams and board with these Movers & Shakers.
Spark Therapeutics to Invest $575M in New 500k Square Foot State-of-the-Art Gene Therapy Innovation Center on Drexel’s University City Campus
Spark Therapeutics today announced plans to invest an initial $575M in the creation of a new, state-of-the-art gene therapy innovation center on Drexel University’s campus in the heart of Philadelphia’s University City neighborhood.
Spark Therapeutics Updated SPK-8011 Data from Phase 1/2 Study Shows Multi-Year, Durable Factor VIII (FVIII) Expression that Significantly Reduced Bleeding in Hemophilia A Patients
Spark Therapeutics, a member of the Roche Group and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced data from its Phase 1/2 clinical trial of investigational SPK-8011 in hemophilia A.
Collaboration is key to faster breakthroughs. The NIH, FDA, and 15 private organizations have announced they are joining forces for the sake of the 30 million Americans suffering from a rare disease.
Spark Therapeutics and CombiGene Enter into Exclusive, Global Licensing Agreement for Gene Therapy Candidate CG01
Spark Therapeutics and CombiGene AB (‘CombiGene’) today announced the signing of an exclusive collaboration and licensing agreement for CombiGene’s CG01 project, an investigational gene therapy which aims to treat drug resistant focal epilepsy.
Takeda entered into a licensing pact with Poseida, Spark entered into a licensing agreement with CombiGene AB, while BridgeBio Pharma announced plans for its second annual R&D Day.
Unlike most companies addressing the diseases associated with aging, Rejuvenate Bio tackles multiple cardiac, metabolic and renal issues at once.
With the planned departure from its 561,652-square-foot RTP campus, GSK will reduce its geographical footprint, but not its staff.
As the city rapidly develops as a biopharma hub, wet lab space is rapidly dwindling.
The startup’s initial focus will be on rare blindness conditions affecting pediatric patients.
NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease
NeuExcell Therapeutics and Spark Therapeutics, a member of the Roche Group announced a gene therapy collaboration aimed at developing a safe and effective treatment for patients suffering from Huntington's Disease.
The oncogenicity and neurotoxicity risks of AAVs and possible mitigation strategies were the primary focus on Thursday.
The collaboration between Spark and NeuExcell increased the hope for Huntington's disease cure in near future. This is going to be a great relief for all the patients.